WASHINGTON D.C. — A bill making its way through Congress that takes aim at selecting Chinese biotech firms and blocking them from doing business in the United States has quietly raised concerns among Delaware’s biotech industry. The Biosecure Act was released from the House Committee on Oversight and Accountability on May 15. Specifically, the bill
To continue reading this article ...
Subscribe to Delaware Business Times right now and get access to subscriber-only content like this article. Plus get 24 issues of DBT via print or digital, special bonus issues, and discounted registration for our in-person events.